HCA Healthcare (HCA), the United States’ largest hospital chain, beat Wall Street on both revenue and profit for the second quarter, then watched its own stock fall anyway.
The reason sits inside a single line item: a roughly $400 million pre-tax hit tied to patients losing health insurance coverage.
That number, and what it says about the rest of 2026, is why investors treated a strong quarter as a warning.
What the $400 million hit to HCA means for the quarter
HCA reported adjusted earnings of $7.59 a share on revenue of $20.23 billion, topping the roughly $7.40 that analysts expected, Investing.com reported.
On a GAAP basis, diluted earnings came in at $7.62 a share, up from $6.83 a year earlier.
Underneath the beat sat the problem. HCA said a shift in its payer mix cut pre-tax income by about $400 million during the quarter.
Payer mix is the balance between patients whose care is paid by insurers or government programs and patients who pay little or nothing.
When more patients arrive uninsured, HCA still treats them, but it collects far less, and that gap lands as bad debt.
JHVEPhoto / Getty Images
Why HCA’s health insurance exchange problem is getting bigger
Changes to eligibility rules and reductions in subsidies on the government-run health insurance exchanges, including the Affordable Care Act marketplace, pushed people off their plans.
HCA had assumed most of those people would find other coverage. That assumption broke.
More Healthcare Stocks:
- UnitedHealth’s earnings comeback hides a risk Wall Street can’t price
- UnitedHealth CFO sends stark warning after earnings
- ACA health insurance premiums rise, forcing millions to drop coverage
CFO Mike Marks told investors the company had expected 80% to 85% of patients losing exchange coverage to become uninsured, but the real figure is closer to one-for-one, GuruFocus noted.
That single revision reset the full-year math.
HCA now expects the exchange headwind to cost between $1.0 billion and $1.2 billion in 2026, nearly double the $600 million to $900 million it projected in April, Fierce Healthcare reported.
How HCA softened the blow this quarter
HCA had an offset ready.
During the quarter, it booked about $400 million in incremental net benefit from Medicaid Supplemental Payment Programs, most of it from a newly approved Florida payment program.
That benefit roughly canceled the payer mix hit for the three months.
Related: Lilly quietly hands Chinese partner its cancer drug
The catch is timing. HCA now expects those Medicaid programs to deliver a net benefit of only $300 million to $500 million for the full year, which implies a smaller cushion in the back half as 2025 approvals roll off.
In plain terms, the offset that saved the second quarter shrinks from here, while the coverage headwind keeps building.
The guidance cut that spooked HCA investors
Management responded by lowering nearly every full-year number, according to the company’s SEC release:
HCA’s revised 2026 guidance
- Adjusted earnings per share: $28.70 to $30.50, down from $29.10 to $31.50
- Revenue: $77.0 billion to $79.5 billion, narrowed from $76.5 billion to $80.0 billion
- Adjusted EBITDA: $15.4 billion to $16.1 billion, down from $15.55 billion to $16.45 billion
- Net income: $6.3 billion to $6.7 billion, down from $6.5 billion to about $7.0 billion
The earnings midpoint of about $29.60 lands below where Wall Street projected, which is the kind of detail that turns a strong quarter into a selloff.
The surgical volume decline adds a second worry for HCA
Coverage was not the only soft spot.
Same-facility inpatient surgeries fell 2.3% year over year, and outpatient surgeries dropped 3.4%, Fierce Healthcare noted.
Surgeries carry higher margins than most hospital services, so a decline there hits profit harder than the volume numbers alone suggest.
CEO Sam Hazen tied part of the softness to exchange attrition and broader affordability pressure on patients.
Core demand still held up. Same-facility admissions rose 2.5% and emergency room visits climbed 3.6%.
That tells you the traffic is there even as the payer mix and the surgical count work against margins.
What Wall Street analysts are telling HCA shareholders now
The analyst reaction split into two camps.
According to Investing.com, Barclays downgraded HCA to Equal weight from Overweight, citing volume and payer mix uncertainty.
Bank of America and Wells Fargo also cut their targets to $370 and $369.
The bulls trimmed but held their ground. Cantor Fitzgerald kept an Overweight rating while cutting its target to about $525, and RBC Capital stuck with an Outperform call.
The wider consensus still points higher. Across 17 analysts, the average target sits at $461.20, a level that implies solid double-digit gains from the recent price around $382.
The bull case that keeps HCA in the conversation
Even with the cut, HCA’s cash engine is intact.
The company generated $2.34 billion in operating cash flow during the quarter, repurchased $2.06 billion of stock.
After that, HCA still had $7.21 billion left under its $10 billion buyback authorization as of June 30, according to Yahoo Finance. It also pays a quarterly dividend of $0.78 a share.
HCA holds a structural edge that a single quarter does not erase.
It runs about 190 hospitals concentrated in fast-growing Sunbelt states, and an aging population keeps feeding demand for hospital care regardless of who is paying.
What HCA investors should watch from here
The near-term story now hangs on one question: does the shift from exchange coverage to uninsured status stabilize, or keep spreading?
Here is what will tell you which way it breaks:
Signals that decide HCA’s 2026
- Whether the exchange-to-uninsured conversion rate holds near one-for-one or eases in the second half
- The size of the Medicaid supplemental benefit as 2025 approvals expire
- Whether inpatient and outpatient surgical volumes recover or keep sliding
- Any move in Washington to restore or extend enhanced exchange subsidies
For long-term holders, the buyback and Sunbelt footprint still support the case, though the coverage headwind now sets a lower ceiling on 2026 earnings than the January outlook did.
For anyone considering a new position, the gap between the stock near $382 and the $461 consensus target reflects real disagreement about how fast the payer mix stabilizes.
Only successive earnings reports showing a stabilizing conversion rate will settle it.
The quarter itself was strong. The reason investors sold it was the part of the report that points at next quarter.
Related: JPMorgan resets LLY stock target on drug demand